Coronary Artery Disease News and Research

Latest Coronary Artery Disease News and Research

Alzheimer's live about half as long as those of similar age without dementia

Age, seriousness of impairment, and the severity of other medical conditions are important indicators of how long an individual might survive after an Alzheimer's disease diagnosis, Eric B. Larson, M.D., M.P.H. and colleagues report in the April 6 Annals of Internal Medicine. Study authors include Linda Teri, Ph.D., recipient of an Alzheimer's Association $1 million Pioneer research grant.

6 Apr 2004

Launch of The Oxford Genetics Knowledge Park by Matt Ridley

The Oxford Genetics Knowledge Park is a partnership between Oxford University and the Oxford Radcliffe Hospitals NHS Trust, and is one of six such Parks nationally, funded by the Departments of Health and Trade and Industry. The aim of the Genetics Knowledge Parks (GKPs) is to translate advances in genetics research into clinical practice.

6 Apr 2004

First large-scale clinical trial of chelation therapy, a controversial treatment for heart disease

NYU Medical Center has begun enrolling patients in the first large-scale clinical trial of chelation therapy, a controversial treatment for heart disease widely practiced by complementary and alternative medicine physicians. The new, government-funded nationwide study will determine whether the therapy benefits people with coronary artery disease, the leading cause of death for both men and women in the United States.

30 Mar 2004

Growth factor protein succeeds in growing new coronary arteries

Three patients of the UC Heart & Vascular Center have grown new coronary artery branches to increase blood flow to the heart after receiving a new growth factor protein (FGF1) in November 2003. All three patients showed improved blood flow to the heart twelve weeks following the injection.

26 Mar 2004

AMT Obtains Orphan Drug Designation for Its LPL Gene Therapy Product

AMT today announced that its adeno-associated viral vector (AAV) expressing lipoprotein lipase (LPL) product has been designated as an orphan medicinal product for the treatment of LPL deficiency by the European Commission. This decision follows a positive recommendation by the European Agency for the Evaluation of Medicinal Products.

22 Mar 2004